- Stocks
- Pharma & Healthcare
- Desh Rakshak
Desh Rakshak share price
NSE: DESHRAKPharma & HealthcareDrug Manufacturers - Specialty & Generic
Desh Rakshak at a glance
With a market capitalisation of ₹19 Cr, it ranks 3610th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 25× trailing earnings, against a return on equity of 0.4% in FY15. In Q1 FY16, the quarter ended 30 Jun 2015, revenue was ₹1 Cr (−12.5% year on year) and net profit ₹0 Cr (−50.0%), on a consolidated basis. Promoters held 50.03% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹19 CrRank 3610 on NSE
- P/E (trailing)
- 25×
- Price to book
- 0.61×FY15
- ROE
- 0.4%FY15
- ROCE
- 2.6%FY15
- Debt to equity
- 0.16FY15
- Net profit margin
- 0.5%FY15
- Book value / share
- ₹14.62FY15
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Desh Rakshak quarterly results
| Quarter | Q1 FY15 | Q4 FY15 | Q1 FY16 |
|---|---|---|---|
| Revenue | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Revenue YoY | — | — | −12.5% |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit YoY | — | — | −50.0% |
| Net margin | 1.8% | 2.9% | 1.0% |
| EPS | — | — | — |
Desh Rakshak financials
| Item | FY14 | FY15 |
|---|---|---|
| Revenue | ₹4 Cr | ₹4 Cr |
| Operating profit | ₹0 Cr | ₹0 Cr |
| Net profit | ₹0 Cr | ₹0 Cr |
| EPS (₹) | ₹0.00 | ₹0.00 |
| Cash from operations | ₹0 Cr | ₹0 Cr |
| Total debt | ₹0 Cr | ₹1 Cr |
| Shareholders' equity | ₹7 Cr | ₹7 Cr |
Desh Rakshak shareholding pattern
| Holder | 30 Sep 2025 | 10 Oct 2025 | 17 Oct 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.07% | 50.07% | 50.07% | 50.03% | 50.03% | 50.03% |
| Non-institutions | 49.93% | 49.93% | 49.93% | 49.97% | 49.97% | 49.97% |
Desh Rakshak vs peers
The listed Pharma & Healthcare companies nearest to Desh Rakshak by market capitalisation.
Ask anything about Desh Rakshak
Pivot answers on the live chart with evidence you can check, and tests strategies against DESHRAK's own history. Try: “Why has DESHRAK moved over the last three months?” · “Backtest a 50-day moving-average crossover on DESHRAK over five years” · “Compare DESHRAK with VINRKLB on margins and valuation”
Frequently asked questions about Desh Rakshak
What is the market cap of Desh Rakshak?
Desh Rakshak's market capitalisation is ₹19 Cr (₹19 Cr) at the 22 Oct 2026 close, ranking 3610th among the NSE companies Pivot tracks.
What is the P/E ratio of Desh Rakshak?
Desh Rakshak trades at a trailing P/E of 25. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 20.
What is the ROE and ROCE of Desh Rakshak?
Return on equity was 0.4% in FY15 and return on capital employed was 2.6% in FY15 (consolidated figures).
Is Desh Rakshak a debt-free company?
No. Desh Rakshak's debt-to-equity ratio was 0.16 in FY15, with total debt of ₹1 Cr.
What were Desh Rakshak's latest quarterly results?
For Q1 FY16 (quarter ended 30 Jun 2015), Desh Rakshak reported revenue of ₹1 Cr, −12.5% year on year, and net profit of ₹0 Cr, −50.0% year on year.
What is the shareholding pattern of Desh Rakshak?
As of 30 Jun 2026: promoters 50.03%, non-institutions 49.97%.
Who are Desh Rakshak's competitors?
The listed Pharma & Healthcare companies closest to Desh Rakshak by market cap are Rekvina Labs, Adeshwar Medite, Maitri, Nidan Lab, Vanta Bioscienc and Venmax Drugs.
Is Desh Rakshak a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Desh Rakshak's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DESHRAK against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text